Eli Lilly & Co. has not given up hope of finding a disease-modifying treatment for Alzheimer's disease, despite many failed attempts, including the recently discontinued Phase III program for the beta secretase cleaving enzyme (BACE) inhibitor lanabecestat.
In fact, Lilly Research Labs President Daniel Skovronsky said in an interview on June 13 – the day after the company and partner AstraZeneca PLC announced the lanabecestat failure –
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?